ImmunoSkin Conference Explores Inflammatory Skin Conditions
The third annual ImmunoSkin conference was held October 26-27 in Barcelona, Spain, highlighting new therapeutic strategies and facilitating exchange about the biological mechanisms of psoriasis and atopic dermatitis through clinical case studies and expert debates.
The event was hosted by Almirall and chaired by Dr. Diamant Thaçi, Director of the Institute and Comprehensive Centre for Inflammation Medicine in Lübeck, Germany.
“The third edition of ImmunoSkin underscored Almirall’s long-standing commitment to advancing the scientific understanding of skin and skin conditions, and its role in collaborating with leading experts in the dermatology community to develop novel treatment options,” the company said in a press release.
Leading experts discussed the latest breakthroughs in biological therapies, highlighting the crucial role of IL-13 in atopic dermatitis and the integration of novel biologics into current treatment guidelines. Sessions highlighted new therapeutic strategies and explored the biological mechanisms of psoriasis through clinical case studies and expert debates, providing innovative insights into disease management.
The event also addressed other inflammatory skin conditions, such as chronic spontaneous urticaria, localized scleroderma, and hidradenitis suppurativa, with a focus on holistic approaches to patient care. Presentations emphasized the importance of personalized treatment options and the latest research on the microbiome and intermittent fasting in managing chronic inflammatory skin diseases.
“ImmunoSkin serves as an essential platform for advancing our understanding of autoimmune skin diseases,” Dr. Thaçi said. “By bringing together leading experts in a specialized conference dedicated to inflammatory skin conditions, we foster collaboration and share groundbreaking insights that will ultimately enhance patient care.”
Volker Koscielny, MD, Chief Medical Officer at Almirall, added that the conference allowed for a deep exchange around innovation and areas of unmet need.
“These meetings have an important place to nurture international collaborations and bear testimony to Almirall’s commitment to medical Dermatology,” Dr. Koscielny said.